Abstract
Angiogenesis plays a central role in the development of metastasis in breast cancer. Recent results of large randomized trials show clinically significant improvements in outcomes with the use of bevacizumab in patients with metastatic breast cancer, leading to approval by European and US regulatory agencies. Several other antiangiogenic strategies are in various stages of development. This review discusses the results of recent clinical trials and novel mechanisms of inhibiting angiogenesis, resistance mechanisms, and toxicities; and raises key challenges that face optimal use and development of antiangiogenic agents in breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
